First Page | Meta Content | |
---|---|---|
Document Date: 2013-07-21 05:59:46Open Document File Size: 619,68 KBShare Result on FacebookCityKMD / London / /CompanyRecordati Ireland Ltd. / /CountryGuinea / Japan / United States / South Korea / / /EventFDA Phase / /FacilityCanary Wharf / / /IndustryTermpharmaceutical and biological aspects / treatment of signs and symptoms / suspension solution / pharmaceutical industry / finished product / possible degradation products / technology / chemical name / dissolution media pH / medicinal product / Treatment of the signs and symptoms / aqueous solution / manufacturing processes / manufacturing process / /MedicalConditiontremors / benign prostatic hyperplasia model / BPH / disease / urinary retention / contraction / foil blisters / benign prostatic hyperplasia / contraction in lower urinary tract tissues / MS / /MedicalTreatmentsurgical treatment / /OrganizationEuropean Medicines Agency / CHMP / /PersonRobert James / Antonio Addis / / /Positionmp / /Productfinasteride / tamsulosin hydrochloride / tamsulosin / acetic acid / prazosin hydrochloride / terazosin hydrochloride / mannitol / Silodosin / /ProgrammingLanguageEC / C / /Technologypharmacokinetics / X-ray / PKI / spectroscopy / pharmacodynamics / /URLhttp /SocialTag |